Search - tctmd.com

Displaying 161 - 168 of 168

Sort: Relevancy | Date

Presentation TCT 2012

<b>Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding Dipyridamole In Patients With High On-treatment Platelet Reactivity (ACCEL-DIP) study</b>

Presenter: Yongwhi Park, Young-Hoon Jeong, Jeong-Rang Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang

January 03, 2012

Presentation TCT 2012

Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On Platelet Reactivity In Patients Treated With Clopidogrel

Presenter: Jean-Pierre P. Dery, Abdelouahed Khalil, Ugo D?ry, M?lanie Roy, Pierluigi Tricoci, Richard Becker, Stéphane Rinfret, Éric Larose, G?rald Barbeau, Robert DeLarochelli?re, Josep Rod?s-Cabau, Olivier F. Bertrand

January 03, 2012

Presentation TCT 2012

Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be Attenuated in Diabetic Patients During Therapy with Clopidogrel

Presenter: Rolf P. Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David Flockhart, Zeruesenay Desta, Yan Jin

January 03, 2012

Presentation TCT 2012

Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on Platelet Reactivity After Elective Percutaneous Coronary Intervention

Presenter: Andr?s Kom?csi, Orsolya Rideg, Gy?ngyv?r K?lt?, Andr?s Vorobcsuk, Daniel Aradi

January 03, 2012

Presentation TCT 2012

Genetic Determinants of Clopidogrel Responsiveness in Koreans

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation TCT 2012

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Presenter: Michael V. Holmes

January 03, 2012

Presentation TCT 2012

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Presenter: Ping-Yen Liu, Ling-Jay Hsu, Po-Tseng Lee, Cheng-Hann Lee, Ju-Yi Chen, Yi-Heng Li, Liang-Miin Tsai, Jyh-Hong Chen

January 03, 2012

Advertisement

<b>Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding Dipyridamole In Patients With High On-treatment Platelet Reactivity (ACCEL-DIP) study</b>

Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On Platelet Reactivity In Patients Treated With Clopidogrel

Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be Attenuated in Diabetic Patients During Therapy with Clopidogrel

Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on Platelet Reactivity After Elective Percutaneous Coronary Intervention

Genetic Determinants of Clopidogrel Responsiveness in Koreans

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content